Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction.

Heidenreich PA, Gubens MA, Fonarow GC, Konstam MA, Stevenson LW, Shekelle PG.

J Am Coll Cardiol. 2004 Mar 17;43(6):1019-26.

3.

Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides.

Ng LL, Loke IW, Davies JE, Geeranavar S, Khunti K, Stone MA, Chin DT, Squire IB.

J Am Coll Cardiol. 2005 Apr 5;45(7):1043-50.

4.

[Screening for asymptomatic left ventricular systolic dysfunction in high-risk patients. Preliminary experience with a program based on the use of ECG and natriuretic peptide].

Tarantini L, Cioffi G, Di Lenarda A, Valle R, Pulignano G, Del Sindaco D, Frigo G, Soravia G, Tessier R, Catania G.

G Ital Cardiol (Rome). 2008 Dec;9(12):835-43. Italian.

PMID:
19119693
5.
6.

Clinical criteria and biochemical markers for the detection of systolic dysfunction.

Yamamoto K, Burnett JC Jr, Bermudez EA, Jougasaki M, Bailey KR, Redfield MM.

J Card Fail. 2000 Sep;6(3):194-200.

PMID:
10997744
7.

Evaluation of different strategies for identifying asymptomatic left ventricular dysfunction and pre-clinical (stage B) heart failure in the elderly. Results from 'PREDICTOR', a population based-study in central Italy.

Mureddu GF, Tarantini L, Agabiti N, Faggiano P, Masson S, Latini R, Cesaroni G, Miceli M, Forastiere F, Scardovi AB, Uguccioni M, Boccanelli A.

Eur J Heart Fail. 2013 Oct;15(10):1102-12. doi: 10.1093/eurjhf/hft098. Epub 2013 Jun 20.

8.

Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study.

Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, Levy D.

JAMA. 2002 Sep 11;288(10):1252-9.

PMID:
12215132
9.

B-type natriuretic peptide testing for structural heart disease screening: a general population-based study.

Nakamura M, Tanaka F, Sato K, Segawa T, Nagano M.

J Card Fail. 2005 Dec;11(9):705-12. Erratum in: J Card Fail. 2006 Mar;12(2):170.

PMID:
16360967
10.

Biochemical detection of left-ventricular systolic dysfunction.

McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, Tunstall-Pedoe H, McMurray JJ, Dargie HJ.

Lancet. 1998 Jan 3;351(9095):9-13.

PMID:
9433422
11.

BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction.

Falcão LM, Pinto F, Ravara L, van Zwieten PA.

J Renin Angiotensin Aldosterone Syst. 2004 Sep;5(3):121-9.

PMID:
15526247
12.

Cost-effectiveness of B-type natriuretic peptide testing.

Mueller C.

Congest Heart Fail. 2008 Jul-Aug;14(4 Suppl 1):35-7. Review.

PMID:
18772637
13.

Prognostic value of B-type natriuretic peptide for assessment of left ventricular function in patients with chronic kidney disease.

Soleimani A, Nasiri O, Nikoueinejad H, Mianehsaz E, Yousefzade M, Foroozanfard F, Tabatabaizadeh M, Moraveji SA, Rajali M.

Iran J Kidney Dis. 2011 Jul;5(4):242-7. Erratum in: Iran J Kidney Dis. 2011 Sep;5(5):355. Mianehsaz, Elaheh [added].

14.

Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study.

de Lemos JA, McGuire DK, Khera A, Das SR, Murphy SA, Omland T, Drazner MH.

Am Heart J. 2009 Apr;157(4):746-53.e2. doi: 10.1016/j.ahj.2008.12.017. Epub 2009 Feb 20.

PMID:
19332205
15.

Diagnostic ability of B-type natriuretic peptide and impedance cardiography: testing to identify left ventricular dysfunction in hypertensive patients.

Bhalla V, Isakson S, Bhalla MA, Lin JP, Clopton P, Gardetto N, Maisel AS.

Am J Hypertens. 2005 Feb;18(2 Pt 2):73S-81S.

PMID:
15752936
16.

[NT-proBNP and echocardiography for long-term left ventricular function assessment after acute myocardial infarction treated with primary angioplasty].

Swiatkiewicz I, Grubecki A, Koziński M, Fabiszak T, Białoszyński T, Sukiennik A, Kubica J.

Pol Merkur Lekarski. 2006 Mar;20(117):289-92. Polish.

PMID:
16780257
17.

Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF (St Vincent's Screening TO Prevent Heart Failure) study.

Ledwidge MT, O'Connell E, Gallagher J, Tilson L, James S, Voon V, Bermingham M, Tallon E, Watson C, O'Hanlon R, Barry M, McDonald K.

Eur J Heart Fail. 2015 Jul;17(7):672-9. doi: 10.1002/ejhf.286.

18.

BNP in the community - still work to be done...

Rao A, Hodgson L, Pearce D, Walsh J.

Int J Cardiol. 2008 Feb 29;124(2):228-30. Epub 2007 Mar 23.

PMID:
17363081
19.

Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial.

Ledwidge M, Gallagher J, Conlon C, Tallon E, O'Connell E, Dawkins I, Watson C, O'Hanlon R, Bermingham M, Patle A, Badabhagni MR, Murtagh G, Voon V, Tilson L, Barry M, McDonald L, Maurer B, McDonald K.

JAMA. 2013 Jul 3;310(1):66-74. doi: 10.1001/jama.2013.7588.

PMID:
23821090
20.

A prospective study in search of an optimal B-natriuretic peptide level to screen patients for cardiac dysfunction.

Atisha D, Bhalla MA, Morrison LK, Felicio L, Clopton P, Gardetto N, Kazanegra R, Chiu A, Maisel AS.

Am Heart J. 2004 Sep;148(3):518-23.

PMID:
15389242

Supplemental Content

Support Center